Literature DB >> 6300612

Diphosphonates: history and mechanisms of action.

H Fleisch.   

Abstract

The history of diphosphonates began with studies of inorganic pyrophosphate. This compound was found to occur in many biological fluids and inhibited the precipitation of calcium phosphates. It also slowed the transformation of amorphous calcium phosphate to its crystalline form, and inhibited crystal aggregation and dissolution. These observations suggested that it might be a compound of physiological or pathophysiological significance, perhaps in hypophosphatasia and in renal lithiasis. Diphosphonates are compounds where the P-O-P bond of pyrophosphate is replaced by a P-C-P bond. Many diphosphonates have been synthesized and tested and some relationship of their structure to the spectrum of biological effects has been observed. These analogues have similar properties to pyrophosphate, but unlike pyrophosphate they are resistant to enzymic degradation. Their experimental properties have led to their clinical development as bone scanning agents and in the treatment of disorders of ectopic mineralization and increased bone resorption.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6300612     DOI: 10.1016/0221-8747(81)90044-8

Source DB:  PubMed          Journal:  Metab Bone Dis Relat Res        ISSN: 0221-8747


  25 in total

1.  A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.

Authors:  W D Fraser; T C Stamp; R A Creek; J P Sawyer; C Picot
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

2.  Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.

Authors:  J R Davis; D A Heath
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 3.  Cartilage biology, pathology, and repair.

Authors:  Daniel Umlauf; Svetlana Frank; Thomas Pap; Jessica Bertrand
Journal:  Cell Mol Life Sci       Date:  2010-08-25       Impact factor: 9.261

4.  Mutations in ANKH cause chondrocalcinosis.

Authors:  Adrian Pendleton; Michelle D Johnson; Anne Hughes; Kyle A Gurley; Andrew M Ho; Michael Doherty; Josh Dixey; Pierre Gillet; Damien Loeuille; Rodney McGrath; Antonio Reginato; Rita Shiang; Gary Wright; Patrick Netter; Charlene Williams; David M Kingsley
Journal:  Am J Hum Genet       Date:  2002-09-20       Impact factor: 11.025

Review 5.  Beyond oncology--application of HPMA copolymers in non-cancerous diseases.

Authors:  Xin-Ming Liu; Scott C Miller; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

Review 6.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 7.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.

Authors:  N Varache; M Audran; P Clochon; A Lortholary; G Bouachour; P Alquier; M F Basle
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

Review 9.  Application of xenogeneic stem cells for induction of transplantation tolerance: present state and future directions.

Authors:  Yong-Guang Yang
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

10.  Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.

Authors:  M J Rogers; X Ji; R G Russell; G M Blackburn; M P Williamson; A V Bayless; F H Ebetino; D J Watts
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.